Suppr超能文献

不可切除结直肠癌肝转移的移植治疗:首个前瞻性试点研究的长期随访结果。

Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study.

机构信息

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.

出版信息

Ann Surg. 2023 Aug 1;278(2):239-245. doi: 10.1097/SLA.0000000000005703. Epub 2022 Sep 9.

Abstract

OBJECTIVE

To determine whether liver transplantation (LT) can provide long-term overall survival (OS) in selected patients with nonresectable liver-only colorectal liver metastases (nrCRLM).

BACKGROUND

In 2005 the first prospective pilot study on LT for nrCRLM was initiated in Norway. We here report long-term data from this study.

METHODS

Main inclusion criteria were nrCRLM, excised primary tumors, and 6 weeks of chemotherapy. Carcinoembryonic antigen >80 µg/L, progressive disease on chemotherapy, size of largest lesion >5.5 cm, and <2 years from primary tumor resection to LT were previously found to be associated with survival. The sum of these factors constitutes the Oslo Score.

RESULTS

From 2006 to 2012, 23 patients underwent LT in the study. In February 2022, the actual 5-year and 10-year OS after LT were 43.5% and 26.1%, respectively. All patients alive were observed for more than 10 years (range: 133-168 months). Four patients were alive without signs of cancer and with no evidence for disease of median of 102 months (53-133 months). A fifth patient died of noncancer cause after 164 months with no evidence for disease for 31 months. For patients with Oslo Score of 0 or 1, the 5-year and 10-year actual OS was 75% and 50%, respectively (n=6). For patients with Oslo Score of 2, the 5-year and 10- year actual OS 50% was 33% (n=6). All patients with Oslo score 3 or 4 were deceased 86 months post-LT (n=9).

CONCLUSION

LT for nrCRLM can provide long term survival and perhaps cure for selected patients. The OS is excellent compared to oncological treatment options and in line with results from studies on resectable CRLM.

摘要

目的

确定肝移植(LT)是否能为部分不可切除的肝单发结直肠癌肝转移(nrCRLM)患者提供长期的总生存率(OS)。

背景

2005 年,挪威首次开展了关于 LT 治疗 nrCRLM 的前瞻性试点研究。本研究报告了该研究的长期数据。

方法

主要纳入标准为 nrCRLM、切除的原发肿瘤和 6 周的化疗。癌胚抗原(CEA)>80μg/L、化疗期间疾病进展、最大病灶直径>5.5cm 和 LT 距原发肿瘤切除时间<2 年,先前与生存相关。这些因素的总和构成了奥斯陆评分。

结果

2006 年至 2012 年,共有 23 名患者在该研究中接受了 LT。截至 2022 年 2 月,LT 后实际的 5 年和 10 年 OS 分别为 43.5%和 26.1%。所有存活的患者观察时间均超过 10 年(范围:133-168 个月)。4 名患者无癌症迹象且无疾病证据,中位时间为 102 个月(53-133 个月)。第五名患者在 164 个月后因非癌症原因死亡,无疾病证据 31 个月。对于奥斯陆评分为 0 或 1 的患者,5 年和 10 年实际 OS 分别为 75%和 50%(n=6)。对于奥斯陆评分为 2 的患者,5 年和 10 年实际 OS 为 50%和 33%(n=6)。所有奥斯陆评分 3 或 4 的患者在 LT 后 86 个月死亡(n=9)。

结论

LT 治疗 nrCRLM 可为部分患者提供长期生存甚至治愈。与肿瘤治疗方案相比,OS 非常优异,与可切除的 CRLM 研究结果一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验